Questions to Ask Before Selecting Cheapest Compounded Semaglutide

Ask what the active ingredient is, who compounds it, who prescribes it, and what happens when the dose changes. Compounded semaglutide is not FDA-approved, so the agency does not review it for safety, effectiveness or quality before it is marketed, and answers to those four questions carry more weight than the number on the page.

Before the product: is this the right treatment at all

The first question is directed inward rather than at a seller. Current obesity pharmacotherapy guidance treats these medicines as one part of a longer clinical plan, chosen against a person’s history, other conditions, and other medicines. A program that never raises that question has skipped a step that a prescribing relationship is supposed to include, and the price becomes irrelevant if the treatment was never appropriate.

The second inward question concerns approved alternatives. The FDA’s position is that compounded drugs should be used in patients whose medical needs cannot be met by an FDA-approved drug. Approved semaglutide reaches patients through insurance and through manufacturer cash channels, and the current Wegovy labeling covers an injection and a tablet, so the approved routes are worth pricing before the compounded ones.

Questions about what is in the vial

Ask for the active ingredient exactly as it appears on the label. The FDA has said that some semaglutide sold by compounders may be a salt form, that semaglutide sodium and semaglutide acetate are different active ingredients from those in the approved drugs, and that it is not aware of any lawful basis for their use in compounding. A seller that cannot state plainly which substance is supplied has answered the question.

Ask next whether anything else is mixed in. Combination preparations exist, and they move the product further from the approved medicine while making price comparisons across sellers close to meaningless.

Questions about people, not products

Ask for the name of the dispensing pharmacy and the state that licenses it, then check it with that state’s board of pharmacy. Ask whether the pharmacy operates under section 503A or registers with the FDA as a 503B outsourcing facility, since the second is subject to current good manufacturing practice requirements and FDA inspection while the first is not. Ask who the prescribing clinician is, whether they are licensed where the patient lives, and how to reach them after delivery. The FDA lists a company that ships without screening and a prescription from a licensed doctor among its telehealth warning signs, and lists the absence of a doctor available afterward alongside it.

Comparing published provider pages is part of answering these people-and-product questions before a call. Named options in this space include Ro, Hims and Hers, Henry Meds, and HealthRX, and a page such as the HealthRX compounded semaglutide overview lets a reader see whether the pharmacy category and prescriber arrangement are stated plainly rather than implied. The providers that answer these questions in public are usually the ones that will answer them again in writing when asked directly.

The question list, with disqualifying answers

Question	Why it exists	An answer that ends it
Which ingredient, as labeled?	Salt forms are different active ingredients	Evasion, or a salt form
Which pharmacy dispenses it?	Licensure is verifiable	“We cannot share that”
503A or 503B?	Different quality obligations	The seller does not know
Who prescribes, and where licensed?	A valid prescription requires a clinician	No named clinician
What happens when the dose changes?	Dosing errors are a documented harm	“Follow the instructions in the box”
How is it shipped?	These products need refrigeration	No cold chain, no replacement policy
What is the full price schedule?	Introductory pricing hides the running cost	Only a first-month figure
How is cancellation handled?	Terms should precede payment	Terms shown only after purchase

Questions about the months after the first order

Ask how a dose change is authorized and who calculates it. The FDA has received multiple adverse event reports, some involving hospitalization, that may relate to dosing errors with compounded injectable semaglutide, including patients measuring and self-administering incorrect doses and health care professionals miscalculating them. It has also received reports involving doses beyond what appears in the approved labeling, including larger single doses and faster escalation. Those are clinician-side decisions, and the right question is who makes them and how they reach the patient.

Ask what happens on stopping. The STEP 1 trial extension followed participants after semaglutide was withdrawn and documented substantial regain of lost weight, and the STEP 4 trial compared continued treatment against a switch to placebo. Those results describe the approved medicine, but they frame the real decision: a program is a running cost with a defined consequence for stopping, not a one-time purchase.

Questions to ask about the price itself

Ask what the fee includes, what it excludes, what changes at higher strengths, and what a year costs rather than a month. Published schedules make this answerable, which is why cash-pay practices such as Henry Meds and FormBlends and telehealth platforms including Ro and Hims and Hers can be compared on paper, while manufacturer channels such as NovoCare Pharmacy and LillyDirect publish terms for approved products. Then ask why a figure is well below all of them. Deep discounts and prices that seem too good to be true appear on the FDA’s own telehealth warning list, and the agency has documented fraudulent compounded semaglutide with false label information behind exactly that kind of number.

Frequently asked questions

Is it reasonable to ask for the pharmacy’s name in writing?

Yes, and the response is informative either way. The FDA advises obtaining a prescription and filling it at a state-licensed pharmacy, so a seller unwilling to identify the dispensing pharmacy has placed itself outside the structure that advice depends on. A licensed operation answers the question routinely.

What if a provider says its product is identical to the brand?

Treat that as a reason to stop. The FDA lists a claim that a compounded drug is the same as an FDA-approved drug among its telehealth warning signs. Approval is a regulatory status earned through review, not a description of similarity, and no compounded preparation carries it.

Should lab work be expected before starting?

That is a clinical judgment rather than a fixed rule, which is why the useful question is who decides and whether that clinician is named and reachable. A program with no mechanism for ordering or reviewing testing has narrowed itself to shipping, which is a different service from prescribing.

Do questions about cancellation matter this early?

They matter most early, because the terms are hardest to obtain once a card is on file. Minimum terms, refund policy, and what happens to an unshipped prepaid order are all knowable before payment, and a provider that will not state them before purchase is describing how it intends to behave later.

Sources

• FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• FDA, Compounding and the FDA: Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA, Human Drug Compounding Laws: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
• FDA, BeSafeRx: Your Source for Online Pharmacy Information: https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
• DailyMed, Wegovy labeling: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. PubMed: https://pubmed.ncbi.nlm.nih.gov/35441470/
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: the STEP 4 randomized clinical trial. PubMed: https://pubmed.ncbi.nlm.nih.gov/33755728/
• Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. PubMed: https://pubmed.ncbi.nlm.nih.gov/40789597/